Many individuals with chronic myeloid leukemia have benefited from the drug imatinib (Gleevec)—but if they are taken off the drug, relapse occurs. Two mathematical models to explain this phenomenon, one described in this issue, have come to different conclusions (1181–1184).
This is a preview of subscription content, log in via an institution to check access.
Kim Caesar
References
Smith, J.K., Mamoon, N.M. & Duhe, R.J. Oncol. Res. 14, 175–225 (2004).
Druker, B.J. Adv. Cancer Res. 91, 1–30 (2004).
Gorre, M.E. et al. Science 293, 876–880 (2001).
Cortes, J., O'Brien, S. & Kantarjian, H. Blood 104, 2204–2205 (2004).
Higashi, T. et al. Am. J. Hematol. 76, 275–278 (2004).
Michor, F. et al. Nature 435, 1267–1270 (2005).
Roeder, I. et al. Nat. Med. 12, 1181–1184 (2006).
Melo, J.V., Hughes, T.P. & Apperley, J.F. Hematology Am. Soc. Hematol. Educ. Program 2003, 132–152 (2003).
Wodarz, D. & Komarova, N.L. Computational Biology of Cancer: Lecture Notes and Mathematical Modeling (World Scientific Publishing, Singapore, 2005).
Graham, S.M. et al. Blood 99, 319–325 (2002).
Jorgensen, H.G. et al. Clin. Cancer Res. 12, 626–633 (2006).
Komarova, N.L. & Wodarz, D. Proc. Natl. Acad. Sci. USA 102, 9714–9719 (2005).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wodarz, D. Targeted cancer treatment: resisting arrest. Nat Med 12, 1125–1126 (2006). https://doi.org/10.1038/nm1006-1125
Issue Date:
DOI: https://doi.org/10.1038/nm1006-1125
- Springer Nature America, Inc.